Join to View Full Profile
1100 Fairview Ave N# D5-100Seattle, WA 98109
Phone+1 206-618-5181
Fax+1 206-606-1025
Dr. Veatch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2013 - 2016- University of WashingtonResidency, Internal Medicine, 2010 - 2013
- University of Washington School of MedicineClass of 2010
Certifications & Licensure
WA State Medical License 2010 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Tumor Regression Following Engineered Polyomavirus-Specific T Cell Therapy in Immune Checkpoint Inhibitor-Refractory Merkel Cell Carcinoma.Yuta Asano, Joshua Veatch, Megan McAfee, Jakob Bakhtiari, Bo Lee
Medrxiv. 2024-07-05 - 16 citationsImmune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies.Erica T Goddard, Miles H Linde, Shivani Srivastava, Grant Klug, Tamer B Shabaneh
Cancer Cell. 2024-01-08 - Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma.Lisa May Ling Tachiki, Daniel S Hippe, Karly Williams Silva, Evan Thomas Hall, William McCamy
Cancer Immunology, Immunotherapy. 2023-12-01
Press Mentions
Tip Sheet: New Insights on RSV and Malaria, Metastatic Breast Cancer Resources for Patients — and Fred Hutch at ASHDecember 5th, 2024- New Initiative Bolsters Washington State Life SciencesNovember 19th, 2024
Grant Support
- Targeting the tumor microenvironment with engineered CD4+ T cellsFRED HUTCHINSON CANCER CENTER2024–2029
- Targeting the tumor microenvironment with engineered CD4+ T cellsFRED HUTCHINSON CANCER CENTER2024–2029
- Therapeutic applications of CD4+ T cells specific for oncogenic driver mutationsFRED HUTCHINSON CANCER CENTER2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
